Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

BACKGROUND: Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Hurkmans, Daan P., Sassen, Sebastiaan D.T., de Joode, Karlijn, Putter, Lisanne, Basak, Edwin A., Wijkhuijs, Annemarie J.M., Joerger, Markus, Debets, Reno, Koch, Birgit C.P., Van der Leest, Cor H., Schreurs, Marco W.J., van der Veldt, Astrid A.M., Aerts, Joachim G.J.V., Mathijssen, Ron H.J., Koolen, Stijn L.W.
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2021
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183294/
https://ncbi.nlm.nih.gov/pubmed/34088739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002344
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items